



## Venue Information:

**Utrecht**

24th September 2014



Rooseveltlaan 100, 3526 Utrecht (The Netherlands)



We look forward to meeting you aboard the Ocean Diva Futura!



## Innovation, safety and efficiency in pharmacy workflow

**24th September 2014**

Utrecht – The Netherlands

14h00 - 21h30

*Accreditation request has been submitted*





BD is proud to be hosting a Pharmacy Symposium, focusing on Innovation, Safety and Efficiency in pharmacy workflow.

This event will provide an open environment for information sharing on best practice and key challenges associated with the safe and efficient management of hazardous drugs.

The symposium will consist of a number of interactive sessions including e-voting, in addition to ample opportunity to network with leading professional peers from across The Netherlands.

Date: **24th September 2014**

Venue: **Utrecht**

14.00: **Boarding and welcome**

14.30: **Opening event**

14.45: **Start interactive session with Key Opinion Leaders and e-voting**

**- Contamination risks in the handling of toxic drugs**

*Paul Sessink, Exposure Control, Bohus-Björkö, Sweden*

**- Implementation of a CSTD to improve healthcare worker safety and reduce drug waste**

*Johan Vandenbroucke, UZ Gent, Belgium*

**- Reproductive Health and Chromosomal Effects of Occupational Exposure to Hazardous Drugs**

*Melissa McDiarmid, Baltimore, USA*

**- Optimise safety and traceability of preparations in hospital pharmacy through software implementation**

*Isabelle Larosche, Centre Hospitalier of Luxemburg, GD Luxemburg*

18.00: **Conclusions**

19.00: **Walking dinner while enjoying the Utrecht skyline**

21.30: **Disembark**

## Speaker Biographies

### Dr. Paul J.M. Sessink PhD

Dr. Paul J.M. Sessink studied organic chemistry and toxicology at the University of Nijmegen. In November 1996 he attained a PhD degree in Medical Sciences at the University of Nijmegen by defending his thesis entitled: "Monitoring of occupational exposure to antineoplastic agents".

In 1995 he founded Exposure Control B.V., a consulting firm that offers methods for environmental and biological monitoring of occupational exposure to antineoplastic drugs and other pharmaceuticals in hospitals and in the pharmaceutical industry (sampling/analysis/advice). Dr. Sessink is co-author of approximately 40 scientific publications regarding environmental and biological monitoring of occupational exposure to antineoplastic drugs.

For more information, visit [www.exposurecontrol.nl](http://www.exposurecontrol.nl)



### Johan Vandenbroucke PharmD



Having qualified as a pharmacist in 1979 and obtained a Pharm D in Hospital Pharmacy in 1981, Johan started working in the central pharmacy of the University Hospital Ghent in August 1979. In 1986 he worked as the Scientific Manager for the B. Braun Company of Belgium, then returned to UZ Ghent in 1987, becoming increasingly involved in oncology.

In 2000, Johan was promoted to Senior Pharmacist of Production and cofounded in 2005 the Belgian Oncology Pharmacy Practitioners (BOPP). Between 2003-2007, Johan co-chaired the ISOPP Standards Committee together with colleagues in Australia and USA with the first priority being the development of an ISOPP standard for safe handling of hazardous drugs, published in 2007. In the same year, Johan then became a secretariat member of ISOPP and in 2008 was elected as President Elect, and subsequently President of ISOPP between 2010-2012. Johan now retains the position of Treasurer.

### Prof. Melissa McDiarmid MD, MPH

Dr. McDiarmid received her M.D. from the University of Maryland at Baltimore in 1979, and her M.P.H. from The Johns Hopkins School of Public Health in 1986. She is board-certified in Internal Medicine, Occupational Medicine and Toxicology. Dr. McDiarmid was Director of the Office of Occupational Medicine for the U.S. Occupational Safety & Health Administration (OSHA) in Washington, D.C., from 1991 until 1996.

A principal career focus for Dr. McDiarmid has been describing the effects from and preventing exposure of healthcare workers to hazardous drugs. While at OSHA she wrote much of its Safe Handling Guidelines for Antineoplastic Drugs and was a member of the NIOSH Alert workgroup on Safe Handling. Currently, Dr. McDiarmid is Professor of Medicine and Director of the University of Maryland School of Medicine's Occupational Health Program.



### Dr Isabelle Larosche, PharmD, PhD

Isabelle received her PharmD and postgraduate degree in Toxicology from the University René Descartes Paris and then joined INSERM (French National Institute for Health) where she obtained her PhD in 2008 for her work on xenobiotic-induced mitochondrial alterations and liver disease. In 2011 she joined the production department at Centre Hospitalier of Luxemburg which comprises both the cytotoxic production unit and the IV/non sterile production unit. Constantly striving to enhance safety, centralized production of cytotoxic drugs was implemented in 2004 and currently around 10 000 doses are prepared annually. In 2012, software-assisted prescription, preparation and administration was launched to further improve medication safety and efficiency.

Visit the website [www.MedicationWorkflow.com](http://www.MedicationWorkflow.com) and

**REGISTER NOW**